Both hepatitis B (HB) and nonalcoholic fatty liver disease (NAFLD) are related to metabolic syndrome (MetS); however, this relationship remains controversial. In this study, we determined the effects of NAFLD and HB infection on the risk of MetS among elderly individuals.
Methods:
In total, 24,500 individuals aged >65 years were enrolled; they were classified into four groups: normal individuals (N), patients with only HB infection without abnormal echogenicity (HB-alone), patients with only abnormal echogenicity or fatty liver alone (FL-alone), and patients with both HB infection and abnormal echogenicity (HB-FL).
Results:
After adjustment for age, compared with group N, men and women with NAFLD (FL-alone and HB-FL) had a significantly higher risk of MetS, whereas no significant difference was observed in the incidence of MetS between groups HB-alone and N. However, group HB-FL had a lower risk of MetS than did group FL-alone. HB infection (HB-alone and HB-FL) was associated with a lower risk of high triglycerides (TGs) and fasting plasma glucose (FPG) than HB infection absence (groups N and FL-alone) in men and women. Lower risk of TG derangement was observed in group HB-alone than in group N. In addition, both men and women in group HB-FL had a lower risk of TG and FPG abnormalities than in group FL-alone, whereas a decrease in incidence of high waist circumference and blood pressure was observed only in men.
Conclusion:
HB infection protects against MetS development, only in patients with HB infection and NAFLD, but not in normal individuals. Additional studies are warranted to clarify the pathogenesis.
Get full access to this article
View all access options for this article.
References
1.
VegaGL. Results of expert meetings: Obesity and cardiovascular disease. Obesity, the metabolic syndrome, and cardiovascular disease. Am Heart J, 2001; 142:1108–1116.
2.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA, 2001; 285:2486–2497.
3.
HsuCH, WangJY, ChenYL, et al.Relationships between alanine aminotransferase levels, abnormal liver echogenicity, and metabolic syndrome. J Am Board Fam Med, 2011; 24:407–414.
4.
WangJY, ChenYL, HsuCH, et al.Predictive value of serum uric acid levels for the diagnosis of metabolic syndrome in adolescents. J Pediatr, 2012; 161:753–756 e2.
5.
YounossiZM, McCulloughAJ. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: Impact on disease progression and treatment response. Liver Int, 2009; 29Suppl 2:3–12.
6.
FeldmanA, EderSK, FelderTK, et al.Clinical and metabolic characterization of lean caucasian subjects with non-alcoholic fatty liver. Am J Gastroenterol, 2017; 112:102–110.
7.
WaitS, ChenDS. Towards the eradication of hepatitis B in Taiwan. Kaohsiung J Med Sci, 2012; 28:1–9.
8.
DasUN. Beneficial role of bioactive lipids in the pathobiology, prevention, and management of HBV, HCV and alcoholic hepatitis, NAFLD, and liver cirrhosis: A review. J Adv Res, 2019; 17:17–29.
9.
ChengYL, WangYJ, KaoWY, et al.Inverse association between hepatitis B virus infection and fatty liver disease: A large-scale study in populations seeking for check-up. PLoS One, 2013; 8:e72049.
10.
Ministry of The Interior ROC (Taiwan). Accessed at www.moi.gov.tw/stat/life.aspx on September, 14, 2019.
11.
Ministry of Health and Welfare ROC (Taiwan). Accessed at http://iiqsw.mohw.gov.tw/InteractiveIntro.aspx?TID=FBDDE8C75ADDA0A1 on September, 14, 2019.
12.
AlbertiKG, EckelRH, GrundySM, et al.Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 2009; 120:1640–1645.
13.
Ministry of Health and Welfare ROC (Taiwan). Accessed at www.hpa.gov.tw/Pages/Detail.aspx?nodeid=639&pid=1219 on September, 14, 2019.
14.
SaverymuttuSH, JosephAE, MaxwellJD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed), 1986; 292:13–15.
15.
YounossiZM, KoenigAB, AbdelatifD, et al.Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016; 64:73–84.
16.
SayinerM, KoenigA, HenryL, et al.Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis, 2016; 20:205–214.
17.
TarantinoG, FinelliC. What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?. World J Gastroenterol, 2013; 19:3375–3384.
18.
EASL-EASD-EASO. Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol, 2016; 64:1388–1402.
19.
FengRN, DuSS, WangC, et al.Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol, 2014; 20:17932–17940.
20.
Almeda-ValdesP, Aguilar-OlivosN, UribeM, et al.Common features of the metabolic syndrome and nonalcoholic fatty liver disease. Rev Recent Clin Trials, 2014; 9:148–158.
21.
ChengJY, WongVW, TseYK, et al.Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B. Hepatology, 2016; 64:1507–1517.
22.
BettermannK, HohenseeT, HaybaeckJ. Steatosis and steatohepatitis: Complex disorders. Int J Mol Sci, 2014; 15:9924–9944.
23.
BaffyG. Kupffer cells in non-alcoholic fatty liver disease: The emerging view. J Hepatol, 2009; 51:212–223.
24.
BetrapallyNS, GillevetPM, BajajJS. Changes in the intestinal microbiome and alcoholic and nonalcoholic liver diseases: Causes or effects?. Gastroenterology, 2016; 150:1745–1755 e3.
25.
TilgH, MoschenAR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology, 2010; 52:1836–1846.
26.
DoS. The natural history of hepatitis B in Asian Americans. Asian Am Pac Isl J Health, 2001; 9:141–153.
27.
WangCC, TsengTC, KaoJH. Hepatitis B virus infection and metabolic syndrome: Fact or fiction?. J Gastroenterol Hepatol, 2015; 30:14–20.
28.
YenSL, ChiuTY, LinYC, et al.Obesity and hepatitis B infection are associated with increased risk of metabolic syndrome in university freshmen. Int J Obes (Lond), 2008; 32:474–480.
29.
SuTC, LeeYT, ChengTJ, et al.Chronic hepatitis B virus infection and dyslipidemia. J Formos Med Assoc, 2004; 103:286–291.
30.
JarcuskaP, JanickoM, KruzliakP, et al.Hepatitis B virus infection in patients with metabolic syndrome: A complicated relationship. Results of a population based study. Eur J Intern Med, 2014; 25:286–291.
31.
JanickoM, SenajovaG, DrazilovaS, et al.Association between metabolic syndrome and hepatitis B virus infection in the Roma population in eastern Slovakia: A population-based study. Cent Eur J Public Health, 2014; 22Suppl:S37–S42.
32.
ZhouY, CuiY, DengH, et al.Association between hepatitis B virus infection and metabolic syndrome: A retrospective cohort study in Shanghai, China. BMC Public Health, 2014; 14:516.
33.
LeeJG, LeeS, KimYJ, et al.Association of chronic viral hepatitis B with insulin resistance. World J Gastroenterol, 2012; 18:6120–6126.
34.
WangCC, HsuCS, LiuCJ, et al.Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol, 2008; 23:779–782.
35.
KangSK, ChungTW, LeeJY, et al.The hepatitis B virus X protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylglucosaminyltransferase III. J Biol Chem, 2004; 279:28106–28112.
36.
ChiangCH, HuangKC. Association between metabolic factors and chronic hepatitis B virus infection. World J Gastroenterol, 2014; 20:7213–7216.
37.
HuangCY, LuCW, LiuYL, et al.Relationship between chronic hepatitis B and metabolic syndrome: A structural equation modeling approach. Obesity (Silver Spring), 2016; 24:483–489.
38.
WannametheeSG, PapacostaO, LawlorDA, et al.Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women's Heart Health Study. Diabetologia, 2012; 55:80–87.
39.
KukJL, ArdernCI. Age and sex differences in the clustering of metabolic syndrome factors: Association with mortality risk. Diabetes Care, 2010; 33:2457–2461.
40.
RelimpioF, Martinez-BroccaMA, Leal-CerroA, et al.Variability in the presence of the metabolic syndrome in Type 2 diabetic patients attending a diabetes clinic. Influences of age and gender. Diabetes Res Clin Pract, 2004; 65:135–142.
41.
RastogiA, SakhujaP, KumarA, et al.Steatosis in chronic hepatitis B: Prevalence and correlation with biochemical, histologic, viral, and metabolic parameters. Indian J Pathol Microbiol, 2011; 54:454–459.
